孟加拉国医学院的观察性研究：伊维菌素可作为PREP为医护人员抗COVID-19的药物
Tarek Alam博士，过去曾与TrialSite News以及来自孟加拉国医学院和Shomman基金会的庞大研究团队一起接受过采访
最近在同行评审《欧洲医学与健康科学杂志》（EJMED）上发表了他们的COVID-19研究，涉及阿拉姆博士所说的“人民的医学”。
结果显着，甚至令人信服。
对照组中60名受试者中，有44名（73.3％）COVID-19阳性，而实验组58名中只有4名（6.9％）最终死于SARS-CoV-2感染，这是COVID- 19
Albeit not a randomized controlled study, these findings are but one of a growing many associated with case series, observational and a few randomized controlled studies
pointing to material evidence that Ivermectin does serve to inhibit and perhaps even block COVID-19.
Of course, more research is required: TrialSite has evangelized for the National Institutes of Health (NIH) to invest in a study.、